BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Del Bello A, Congy-Jolivet N, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Suc B, Duffas JP, Alric L, Bureau C, Danjoux M, Guilbeau-Frugier C, Blancher A, Rostaing L, Kamar N. Prevalence, incidence and risk factors for donor-specific anti-HLA antibodies in maintenance liver transplant patients. Am J Transplant 2014;14:867-75. [PMID: 24580771 DOI: 10.1111/ajt.12651] [Cited by in Crossref: 79] [Cited by in F6Publishing: 66] [Article Influence: 9.9] [Reference Citation Analysis]
Number Citing Articles
1 Cillo U, Bechstein WO, Berlakovich G, Dutkowski P, Lehner F, Nadalin S, Saliba F, Schlitt HJ, Pratschke J. Identifying risk profiles in liver transplant candidates and implications for induction immunosuppression. Transplantation Reviews 2018;32:142-50. [DOI: 10.1016/j.trre.2018.04.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
2 Lee BT, Fiel MI, Schiano TD. Antibody-mediated rejection of the liver allograft: An update and a clinico-pathological perspective. J Hepatol 2021:S0168-8278(21)01957-7. [PMID: 34343613 DOI: 10.1016/j.jhep.2021.07.027] [Reference Citation Analysis]
3 Zaza G, Granata S, Caletti C, Signorini L, Stallone G, Lupo A. mTOR Inhibition Role in Cellular Mechanisms. Transplantation 2018;102:S3-S16. [DOI: 10.1097/tp.0000000000001806] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
4 Wozniak LJ, Hickey MJ, Venick RS, Vargas JH, Farmer DG, Busuttil RW, McDiarmid SV, Reed EF. Donor-specific HLA Antibodies Are Associated With Late Allograft Dysfunction After Pediatric Liver Transplantation. Transplantation. 2015;99:1416-1422. [PMID: 26038872 DOI: 10.1097/tp.0000000000000796] [Cited by in Crossref: 77] [Cited by in F6Publishing: 21] [Article Influence: 12.8] [Reference Citation Analysis]
5 Shapiro AM. Donor-specific Antibody in Pediatric Liver Transplantation-Identifying a Tree by Its Fruit. Transplantation 2015;99:1314-5. [PMID: 26038875 DOI: 10.1097/TP.0000000000000795] [Reference Citation Analysis]
6 Hann A, Osei-Bordom DC, Neil DAH, Ronca V, Warner S, Perera MTPR. The Human Immune Response to Cadaveric and Living Donor Liver Allografts. Front Immunol 2020;11:1227. [PMID: 32655558 DOI: 10.3389/fimmu.2020.01227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
7 Burghuber C, Roberts T, Knechtle S. The clinical relevance of alloantibody in liver transplantation. Transplantation Reviews 2015;29:16-22. [DOI: 10.1016/j.trre.2014.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Ünlü S, Lachmann N, Jara M, Ritschl PV, Wiering L, Eurich D, Denecke C, Biebl M, Chopra S, Gül-Klein S, Schöning W, Schmelzle M, Reinke P, Tacke F, Pratschke J, Öllinger R, Dziodzio T. Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. J Clin Med 2020;9:E3986. [PMID: 33317012 DOI: 10.3390/jcm9123986] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
9 Varma S, Ambroise J, Komuta M, Latinne D, Baldin P, Reding R, Smets F, Stephenne X, Sokal EM. Progressive Fibrosis Is Driven by Genetic Predisposition, Allo-immunity, and Inflammation in Pediatric Liver Transplant Recipients. EBioMedicine. 2016;9:346-355. [PMID: 27333038 DOI: 10.1016/j.ebiom.2016.05.040] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
10 Zhou S, Mitsinikos T, Emamaullee J, Weaver C, Wang L, Shillingford N, Warren M, Bawab JH, Tiwari N, Genyk Y, Thomas D, Parham DM. Clinicopathologic Characteristics of Late Acute Antibody-mediated Rejection in Pediatric Liver Transplantation. Transplantation 2021;105:2045-53. [PMID: 33031223 DOI: 10.1097/TP.0000000000003469] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Willuweit K, Frey A, Bieniek L, Heinold A, Büchter M, Horn PA, Wedemeyer H, Herzer K. HLA class II donor specific antibodies are associated with graft cirrhosis after liver transplant independent of the mean fluorescence intensity level. BMC Gastroenterol 2020;20:288. [PMID: 32854625 DOI: 10.1186/s12876-020-01427-4] [Reference Citation Analysis]
12 Kohut TJ, Barandiaran JF, Keating BJ. Genomics and Liver Transplantation: Genomic Biomarkers for the Diagnosis of Acute Cellular Rejection. Liver Transpl 2020;26:1337-50. [DOI: 10.1002/lt.25812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 O'Leary JG. Donor-specific alloantibodies in liver transplantation: how should we define and improve long-term success? Transpl Int 2015;28:1359-61. [PMID: 26284821 DOI: 10.1111/tri.12661] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
14 Kim H, Yi N, Song EY, Lee K, Lee K, Lee HW, Ahn HY, Yoon KC, Hong SK, Suh K. Preformed donor-specific antibodies do not affect the 1-year allograft survival in living donor liver transplantation. Clin Transplant 2018;32:e13244. [DOI: 10.1111/ctr.13244] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
15 Vionnet J, Sempoux C, Pascual M, Sánchez-fueyo A, Colmenero J. Donor-specific antibodies in liver transplantation. Gastroenterología y Hepatología 2020;43:34-45. [DOI: 10.1016/j.gastrohep.2019.09.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 O'Leary JG, Kaneku H, Banuelos N, Jennings LW, Klintmalm GB, Terasaki PI. Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am J Transplant 2015;15:1003-13. [PMID: 25772599 DOI: 10.1111/ajt.13153] [Cited by in Crossref: 99] [Cited by in F6Publishing: 87] [Article Influence: 14.1] [Reference Citation Analysis]
17 Dao M, Habès D, Taupin JL, Mussini C, Redon MJ, Suberbielle C, Jacquemin E, Gonzales E, Guettier C. Morphological characterization of chronic antibody-mediated rejection in ABO-identical or ABO-compatible pediatric liver graft recipients. Liver Transpl 2018;24:897-907. [PMID: 29704327 DOI: 10.1002/lt.25187] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
18 Barten MJ, Schulz U, Beiras-Fernandez A, Berchtold-Herz M, Boeken U, Garbade J, Hirt S, Richter M, Ruhpawar A, Sandhaus T, Schmitto JD, Schönrath F, Schramm R, Schweiger M, Wilhelm M, Zuckermann A. The clinical impact of donor-specific antibodies in heart transplantation. Transplant Rev (Orlando) 2018;32:207-17. [PMID: 29804793 DOI: 10.1016/j.trre.2018.05.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
19 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Kamar N. Donor-specific antibodies and liver transplantation. Hum Immunol. 2016; Feb 23. [Epub ahead of print]. [PMID: 26916836 DOI: 10.1016/j.humimm.2016.02.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 5.7] [Reference Citation Analysis]
20 O'leary JG, Demetris AJ, Philippe A, Freeman R, Cai J, Heidecke H, Smith C, Hart B, Jennings LW, Catar R, Everly M, Klintmalm GB, Dragun D. Non-HLA Antibodies Impact on C4d Staining, Stellate Cell Activation and Fibrosis in Liver Allografts. Transplantation 2017;101:2399-409. [DOI: 10.1097/tp.0000000000001853] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 4.8] [Reference Citation Analysis]
21 O'Leary JG, Cai J, Freeman R, Banuelos N, Hart B, Johnson M, Jennings LW, Kaneku H, Terasaki PI, Klintmalm GB. Proposed Diagnostic Criteria for Chronic Antibody-Mediated Rejection in Liver Allografts. Am J Transplant. 2016;16:603-614. [PMID: 26469278 DOI: 10.1111/ajt.13476] [Cited by in Crossref: 64] [Cited by in F6Publishing: 47] [Article Influence: 9.1] [Reference Citation Analysis]
22 Couchonnal E, Rivet C, Ducreux S, Dumortier J, Bosch A, Boillot O, Collardeau-Frachon S, Dubois R, Hervieu V, André P, Scoazec JY, Lachaux A, Dubois V, Guillaud O. Deleterious impact of C3d-binding donor-specific anti-HLA antibodies after pediatric liver transplantation. Transpl Immunol 2017;45:8-14. [PMID: 28782692 DOI: 10.1016/j.trim.2017.08.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
23 Del Bello A, Neau‐cransac M, Lavayssiere L, Dubois V, Congy‐jolivet N, Visentin J, Danjoux M, Le Bail B, Hervieu V, Boillot O, Antonini T, Kamar N, Dumortier J. Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies. Liver Transpl 2019;26:256-67. [DOI: 10.1002/lt.25663] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
24 Tokodai K, Miyagi S, Nakanishi C, Hara Y, Nakanishi W, Goto M, Unno M, Kamei T. Impact of the Trough Level of Calcineurin Inhibitor on the Prevalence of Donor-Specific Human Leukocyte Antigen Antibodies During Long-Term Follow-Up After Pediatric Liver Transplantation: Antibody Strength and Complement-Binding Ability. Transplant Direct 2017;3:e196. [PMID: 28795147 DOI: 10.1097/TXD.0000000000000713] [Cited by in Crossref: 8] [Article Influence: 1.6] [Reference Citation Analysis]
25 Bettinotti MP, Zachary AA, Leffell MS. Clinically relevant interpretation of solid phase assays for HLA antibody. Curr Opin Organ Transplant 2016;21:453-8. [PMID: 27200498 DOI: 10.1097/MOT.0000000000000326] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 3.4] [Reference Citation Analysis]
26 Willuweit K, Heinold A, Rashidi-alavijeh J, Heinemann FM, Horn PA, Paul A, Gerken G, Herzer K. Immunosuppression with mTOR inhibitors prevents the development of donor-specific antibodies after liver transplant. Clin Transplant 2017;31:e12974. [DOI: 10.1111/ctr.12974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
27 Kim PT, Demetris AJ, O'Leary JG. Prevention and treatment of liver allograft antibody-mediated rejection and the role of the 'two-hit hypothesis'. Curr Opin Organ Transplant 2016;21:209-18. [PMID: 26918881 DOI: 10.1097/MOT.0000000000000275] [Cited by in Crossref: 39] [Cited by in F6Publishing: 3] [Article Influence: 6.5] [Reference Citation Analysis]
28 Friman S, Tisone G, Nevens F, Lehner F, Santaniello W, Bechstein WO, Zhuvarel SV, Isoniemi H, Rummo OO, Klempnauer J, Anaokar S, Hurst M, Kazeem G, Undre N, Trunečka P. Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study. Transplant Direct 2021;7:e722. [PMID: 34263020 DOI: 10.1097/TXD.0000000000001166] [Reference Citation Analysis]
29 Papachristou M, Fylaktou A, Daoudaki M, Cholongitas E, Karampatakis T, Anastasiou A, Chatzika G, Makrovasili F, Vagiotas L, Karakasi K, Fouzas I. Prevalence and Impact of Reformed and De Novo Anti-HLA Donor-Specific Antibodies in Liver Transplantation. Transplant Proc 2019;51:424-8. [PMID: 30879557 DOI: 10.1016/j.transproceed.2019.01.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Vandevoorde K, Ducreux S, Bosch A, Guillaud O, Hervieu V, Chambon-Augoyard C, Poinsot D, André P, Scoazec JY, Robinson P, Boillot O, Dubois V, Dumortier J. Prevalence, Risk Factors, and Impact of Donor-Specific Alloantibodies After Adult Liver Transplantation. Liver Transpl 2018;24:1091-100. [PMID: 29665189 DOI: 10.1002/lt.25177] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
31 Cousin VL, Rougemont AL, Rubbia-Brandt L, Wildhaber BE, Villard J, Ferrari-Lacraz S, McLin VA. Peripheral Donor-specific Antibodies Are Associated With Histology and Cellular Subtypes in Protocol Liver Biopsies of Pediatric Recipients. Transplantation 2020;104:1633-43. [PMID: 32732841 DOI: 10.1097/TP.0000000000003099] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
32 Baliellas C, Lladó L, Serrano T, Gonzalez-Vilatarsana E, Cachero A, Lopez-Dominguez J, Petit A, Fabregat J. Sinusoidal obstruction syndrome as a manifestation of acute antibody-mediated rejection after liver transplantation. Am J Transplant 2021. [PMID: 34008326 DOI: 10.1111/ajt.16689] [Reference Citation Analysis]
33 Del Bello A, Danjoux M, Congy-jolivet N, Lavayssière L, Esposito L, Muscari F, Kamar N. Histological long-term outcomes from acute antibody-mediated rejection following ABO-compatible liver transplantation: Outcome of antibody mediated rejection. Journal of Gastroenterology and Hepatology 2017;32:887-93. [DOI: 10.1111/jgh.13613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Kovandova B, Slavcev A, Honsova E, Erhartova D, Skibova J, Viklicky O, Trunecka P. De novo HLA Class II antibodies are associated with the development of chronic but not acute antibody-mediated rejection after liver transplantation - a retrospective study. Transpl Int 2020;33:1799-806. [PMID: 33020979 DOI: 10.1111/tri.13763] [Reference Citation Analysis]
35 Grimbert P, Thaunat O. mTOR inhibitors and risk of chronic antibody-mediated rejection after kidney transplantation: where are we now? Transpl Int. 2017;30:647-657. [PMID: 28445619 DOI: 10.1111/tri.12975] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
36 Aday AW, O'Leary JG. Donor-Specific Antibodies' Meaningful Impact on Liver Transplantation. Liver Transpl 2018;24:999-1000. [PMID: 30028076 DOI: 10.1002/lt.25299] [Reference Citation Analysis]
37 Pascual J, Zuckermann A, Djamali A, Hertig A, Naesens M. Rabbit antithymocyte globulin and donor-specific antibodies in kidney transplantation — A review. Transplantation Reviews 2016;30:85-91. [DOI: 10.1016/j.trre.2015.12.002] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
38 Beyzaei Z, Geramizadeh B, Bagheri Z, Karimzadeh S, Shojazadeh A. De Novo Donor Specific Antibody and Long-Term Outcome After Liver Transplantation: A Systematic Review and Meta-Analysis. Front Immunol 2020;11:613128. [PMID: 33424868 DOI: 10.3389/fimmu.2020.613128] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Legaz I, Boix F, López M, Alfaro R, Galián JA, Llorente S, Campillo JA, Botella C, Ramírez P, Sánchez-Bueno F, Pons JA, Moya-Quiles MR, Minguela A, Muro M. Influence of Preformed Antibodies in Liver Transplantation. J Clin Med 2020;9:E708. [PMID: 32151032 DOI: 10.3390/jcm9030708] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
40 Demetris AJ, Bellamy C, Hübscher SG, O’Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant. 2016; Epub ahead of print. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Cited by in Crossref: 230] [Cited by in F6Publishing: 187] [Article Influence: 38.3] [Reference Citation Analysis]
41 San Segundo D, Alonso C, Ruiz P, Romon I, Arias-Loste MT, Cuadrado A, Puente A, Casafont F, López-Hoyos M, Crespo J, Fábrega E. De Novo Donor-Specific Anti-Human Leukocyte Antigen Antibody Detection in Long-Term Adult Liver Transplantation. Transplant Proc 2016;48:2980-2. [PMID: 27932124 DOI: 10.1016/j.transproceed.2016.08.037] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
42 Del Bello A, Congy-Jolivet N, Rostaing L, Kamar N. Incidence of anti-HLA donor specific antibodies in liver-transplant patients given mTOR inhibitors without calcineurin inhibitors. J Hepatol 2014;61:963-5. [PMID: 24999017 DOI: 10.1016/j.jhep.2014.06.029] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
43 Valenzuela NM, Reed EF. Antibody-mediated rejection across solid organ transplants: manifestations, mechanisms, and therapies. J Clin Invest 2017;127:2492-504. [PMID: 28604384 DOI: 10.1172/JCI90597] [Cited by in Crossref: 83] [Cited by in F6Publishing: 36] [Article Influence: 16.6] [Reference Citation Analysis]
44 Kim SC, Foley DP. Donor-specific antibodies in liver transplantation: challenges in diagnosis and determining clinical impact. Curr Opin Organ Transplant 2020;25:549-54. [PMID: 33105198 DOI: 10.1097/MOT.0000000000000825] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
45 Lee M. Antibody-Mediated Rejection After Liver Transplant. Gastroenterology Clinics of North America 2017;46:297-309. [DOI: 10.1016/j.gtc.2017.01.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
46 Wesson RN, Etchill EW, Garonzik-Wang J. Application and interpretation of histocompatibility data in liver transplantation. Curr Opin Organ Transplant. 2017;22:499-504. [PMID: 28708813 DOI: 10.1097/mot.0000000000000450] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
47 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Hebral AL, Bellière J, Kamar N. High tacrolimus intra-patient variability is associated with graft rejection, and de novo donor-specific antibodies occurrence after liver transplantation. World J Gastroenterol 2018; 24(16): 1795-1802 [PMID: 29713132 DOI: 10.3748/wjg.v24.i16.1795] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 27] [Article Influence: 9.3] [Reference Citation Analysis]
48 Sakamoto S, Akamatsu N, Hasegawa K, Ohdan H, Nakagawa K, Egawa H. The efficacy of rituximab treatment for antibody-mediated rejection in liver transplantation: A retrospective Japanese nationwide study. Hepatol Res 2021;51:990-9. [PMID: 33818877 DOI: 10.1111/hepr.13643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Nakano R, Ohira M, Ishiyama K, Ide K, Kobayashi T, Tahara H, Shimizu S, Arihiro K, Imamura M, Chayama K, Tanaka Y, Ohdan H. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report. Transplant Proc 2017;49:1634-8. [PMID: 28838454 DOI: 10.1016/j.transproceed.2017.05.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
50 Del Bello A, Congy-Jolivet N, Danjoux M, Muscari F, Lavayssière L, Esposito L, Cardeau-Desangles I, Guitard J, Dörr G, Milongo D, Suc B, Duffas JP, Alric L, Bureau C, Guilbeau-Frugier C, Rostaing L, Kamar N. De novo donor-specific anti-HLA antibodies mediated rejection in liver-transplant patients. Transpl Int. 2015;28:1371-1382. [PMID: 26303035 DOI: 10.1111/tri.12654] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 9.0] [Reference Citation Analysis]
51 Perbos E, Juinier E, Guidicelli G, Dromer C, Merville P, Billes M, Taupin J, Neau-cransac M. Evolution of donor-specific antibodies (DSA) and incidence of de novo DSA in solid organ transplant recipients after switch to everolimus alone or associated with low dose of calcineurin inhibitors. Clin Transplant 2014;28:1054-60. [DOI: 10.1111/ctr.12418] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
52 Meszaros M, Niemann M, Ursic-Bedoya J, Faure S, Meunier L, Rivière B, Costes-Martineau V, Thevenin C, Pageaux GP. Exploring predicted indirectly recognizable HLA epitopes (PIRCHE-II) in liver transplant recipients on calcineurin inhibitor-free maintenance immunosuppression. A retrospective single center study. Transpl Immunol 2020;59:101272. [PMID: 32061667 DOI: 10.1016/j.trim.2020.101272] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
53 Barreto SG, Brooke-Smith ME, Neo EL, Dolan P, Leibbrandt R, Emery T, Carroll R, Wigg A, Chen JW. Exploring pre-surgery donor-specific antibodies in the context of organ shortage in liver transplant. Langenbecks Arch Surg 2019;404:865-74. [PMID: 31748871 DOI: 10.1007/s00423-019-01831-9] [Reference Citation Analysis]
54 O'Leary JG, Smith C, Cai J, Hart B, Jennings LW, Everly M, Klintmalm GB, Demetris AJ. Chronic AMR in Liver Transplant: Validation of the 1-Year cAMR Score's Ability to Determine Long-term Outcome. Transplantation 2017;101:2062-70. [PMID: 28452922 DOI: 10.1097/TP.0000000000001802] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
55 Liu W, Wang K, Xiao YL, Liu C, Gao W, Li DH. Clinical relevance of donor-specific human leukocyte antigen antibodies after pediatric liver transplantation. Exp Ther Med 2021;22:867. [PMID: 34194545 DOI: 10.3892/etm.2021.10299] [Reference Citation Analysis]
56 Neuberger JM, Bechstein WO, Kuypers DR, Burra P, Citterio F, De Geest S, Duvoux C, Jardine AG, Kamar N, Krämer BK, Metselaar HJ, Nevens F, Pirenne J, Rodríguez-Perálvarez ML, Samuel D, Schneeberger S, Serón D, Trunečka P, Tisone G, van Gelder T. Practical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group. Transplantation 2017;101:S1-S56. [PMID: 28328734 DOI: 10.1097/TP.0000000000001651] [Cited by in Crossref: 114] [Cited by in F6Publishing: 43] [Article Influence: 22.8] [Reference Citation Analysis]
57 Wadström J, Ericzon BG, Halloran PF, Bechstein WO, Opelz G, Serón D, Grinyó J, Loupy A, Kuypers D, Mariat C, Clancy M, Jardine AG, Guirado L, Fellström B, O'Grady J, Pirenne J, O'Leary JG, Aluvihare V, Trunečka P, Baccarani U, Neuberger J, Soto-Gutierrez A, Geissler EK, Metzger M, Gray M. Advancing Transplantation: New Questions, New Possibilities in Kidney and Liver Transplantation. Transplantation 2017;101 Suppl 2S:S1-S41. [PMID: 28125449 DOI: 10.1097/TP.0000000000001563] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.8] [Reference Citation Analysis]
58 Koo J, Wang HL. Acute, Chronic, and Humoral Rejection. Surgical Pathology Clinics 2018;11:431-52. [DOI: 10.1016/j.path.2018.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
59 OʼLeary JG, Samaniego M, Barrio MC, Potena L, Zeevi A, Djamali A, Cozzi E. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation 2016;100:39-53. [PMID: 26680372 DOI: 10.1097/TP.0000000000000869] [Cited by in Crossref: 73] [Cited by in F6Publishing: 21] [Article Influence: 12.2] [Reference Citation Analysis]
60 Kivelä JM, Kosola S, Peräsaari J, Mäkisalo H, Jalanko H, Holmberg C, Pakarinen MP, Lauronen J. Donor-specific antibodies after pediatric liver transplantation: a cross-sectional study of 50 patients. Transpl Int 2016;29:494-505. [PMID: 26806435 DOI: 10.1111/tri.12747] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
61 Avila CL, Zimmerer JM, Elzein SM, Pham TA, Abdel-Rasoul M, Bumgardner GL. mTOR Inhibition Suppresses Posttransplant Alloantibody Production Through Direct Inhibition of Alloprimed B Cells and Sparing of CD8+ Antibody-Suppressing T cells. Transplantation 2016;100:1898-906. [PMID: 27362313 DOI: 10.1097/TP.0000000000001291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
62 Dumortier J, Dedic T, Erard-poinsot D, Rivet C, Guillaud O, Chambon-augoyard C, Bosch A, Lachaux A, Couchonnal E, Thaunat O, Boillot O, Dubois V. Pregnancy and donor-specific HLA-antibody-mediated rejection after liver transplantation: “Liaisons dangereuses”? Transplant Immunology 2019;54:47-51. [DOI: 10.1016/j.trim.2019.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
63 Demetris AJ, Zeevi A, O'Leary JG. ABO-compatible liver allograft antibody-mediated rejection: an update. Curr Opin Organ Transplant. 2015;20:314-324. [PMID: 25944231 DOI: 10.1097/mot.0000000000000194] [Cited by in Crossref: 38] [Cited by in F6Publishing: 6] [Article Influence: 5.4] [Reference Citation Analysis]
64 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Reference Citation Analysis]
65 Zimmerman MA, Schiller J, Kim J, Martin A, Selim M, Nydam TL, Cronin D 2nd, Hong JC. Pathologic sequelae of allosensitization in liver transplantation. J Surg Res 2016;200:195-9. [PMID: 26253457 DOI: 10.1016/j.jss.2015.06.047] [Reference Citation Analysis]
66 Tokodai K, Miyagi S, Nakanishi C, Hara Y, Nakanishi W, Miyazawa K, Shimizu K, Murakami K, Sasano H, Goto M, Unno M, Kamei T. Association of post-transplant donor-specific HLA antibody with liver graft fibrosis during long-term follow-up after pediatric liver transplantation. Pediatr Transplant. 2018;22:e13169. [PMID: 29542229 DOI: 10.1111/petr.13169] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
67 Hogen R, DiNorcia J, Dhanireddy K. Antibody-mediated rejection: what is the clinical relevance? Curr Opin Organ Transplant 2017;22:97-104. [PMID: 28060025 DOI: 10.1097/MOT.0000000000000391] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
68 Harrington CR, Yang GY, Levitsky J. Advances in Rejection Management: Prevention and Treatment. Clin Liver Dis 2021;25:53-72. [PMID: 33978583 DOI: 10.1016/j.cld.2020.08.003] [Reference Citation Analysis]
69 Del Bello A, Congy-Jolivet N, Audry B, Antoine C, Esposito L, Hebral AL, Kamar N. Impact of transplant accessibility for sensitized patients by avoiding unacceptable antigens. Liver Transpl 2017;23:880-6. [PMID: 28477360 DOI: 10.1002/lt.24781] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Thaunat O, Koenig A, Leibler C, Grimbert P. Effect of Immunosuppressive Drugs on Humoral Allosensitization after Kidney Transplant. J Am Soc Nephrol 2016;27:1890-900. [PMID: 26872489 DOI: 10.1681/ASN.2015070781] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 6.2] [Reference Citation Analysis]
71 Wozniak LJ, Venick RS. Donor-specific antibodies following liver and intestinal transplantation: Clinical significance, pathogenesis and recommendations. International Reviews of Immunology 2019;38:106-17. [DOI: 10.1080/08830185.2019.1630404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
72 Tamura K, Tohyama T, Watanabe J, Nakamura T, Ueno Y, Inoue H, Honjo M, Sakamoto K, Takai A, Ogawa K, Takada Y. Preformed donor-specific antibodies are associated with 90-day mortality in living-donor liver transplantation. Hepatol Res 2019;49:929-41. [PMID: 30991451 DOI: 10.1111/hepr.13352] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]